Anti-VEGFR2/KDR/Flk-1/CD309 Rabbit Polyclonal Antibody for WB and ELISA - P35918

Core Product Specifications and Parameters

Biological Background: VEGFR2/KDR/Flk-1/CD309 Function and Localization

• Vascular endothelial growth factor receptor 2 (VEGFR2), also known as fetal liver kinase 1 (FLK-1) or kinase NYK, is a tyrosine-protein kinase receptor encoded by the Kdr gene in mouse.
• It acts as a cell-surface receptor for VEGFA, VEGFC, and VEGFD, playing an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis.
• Upon ligand binding, VEGFR2 activates multiple signaling cascades including PLCG1, MAPK1/ERK2, MAPK3/ERK1, and AKT1 pathways, promoting endothelial cell proliferation, survival, migration, and differentiation.
• Isoforms lacking a transmembrane domain, such as isoform 2, may function as decoy receptors to negatively regulate VEGFA- and VEGFC-mediated lymphangiogenesis.
• Subcellular localization includes cell membrane, cytoplasm, nucleus, endoplasmic reticulum, cell junction, and early endosome; it can also be secreted.
• Expression is detected in endothelial cells, with high levels in adult heart, lung, kidney, brain, and skeletal muscle, and lower levels in most other adult tissues.
• Key post-translational modifications include phosphorylation and glycosylation, and the receptor contains immunoglobulin-like domains and a kinase domain.

Experimental Guidance and Technical Tips

• Since the immunogen corresponds to the extracellular domain (aa 20-762) of mouse VEGFR2, this antibody may recognize both full-length and shed/soluble forms of the receptor.
• For Western blot, a band at ~150 kDa is expected under reducing conditions; however, glycosylation may cause a slight shift. Use appropriate molecular weight markers and validate with known positive controls from mouse endothelial tissue or cell lines.
• For ELISA, consider using serial dilutions of the antibody and compare with a negative control to optimize signal-to-noise ratio. Confirm specificity with recombinant VEGFR2 protein if available.
• As a polyclonal antibody, experimental conditions such as dilution factors should be optimized for each lot and application. Cross-reactivity with related family members (e.g., FLT1, FLT4) cannot be excluded; use specific inhibitors or knockout samples for validation.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with one-stop access to IVD raw materials, technical services, and consulting, covering every stage from concept to clinic. For angiogenesis and vascular biology research, we offer a range of validated antibody pairs, optimized monoclonal and polyclonal antibodies, and bulk ancillary reagents to support your assay development. We also specialize in sourcing rare target raw materials to accelerate your diagnostic and therapeutic development pipelines.